These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22407972)

  • 41. Issues in use of SAS PROC.MIXED to test the significance of treatment effects in controlled clinical trials.
    Ahn C; Tonidandel S; Overall JE
    J Biopharm Stat; 2000 May; 10(2):265-86. PubMed ID: 10803729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two-stage methods for the analysis of pooled data.
    Stukel TA; Demidenko E; Dykes J; Karagas MR
    Stat Med; 2001 Jul; 20(14):2115-30. PubMed ID: 11439425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.
    Hall DB; Meier U; Diener HC
    Contemp Clin Trials; 2005 Jun; 26(3):349-64. PubMed ID: 15911469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The distribution of the maximum likelihood estimator in up-and-down experiments for quantal dose-response data.
    Vågerö M; Sundberg R
    J Biopharm Stat; 1999 Aug; 9(3):499-519. PubMed ID: 10473034
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Missing data mechanisms in a dose-finding adaptive trial.
    Liu K; Entsuah R
    J Biopharm Stat; 2012; 22(2):329-37. PubMed ID: 22251177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
    Zohar S; Chevret S
    J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of alternative models for linking drug exposure with adverse effects.
    Abrahamowicz M; Beauchamp ME; Sylvestre MP
    Stat Med; 2012 May; 31(11-12):1014-30. PubMed ID: 22095719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):615-31. PubMed ID: 20358440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Dose-response relationship: relevance for medical practice].
    Klinkhardt U; Harder S
    Med Klin (Munich); 2000 May; 95(1 Spec No):9-14. PubMed ID: 10851842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A SAS macro for target dose estimation by reinforced urn processes in phase I clinical trials.
    Zhong C; Zhuo Y; Xia J; Hu S; Li C; Jiang Z; Wang S
    Comput Methods Programs Biomed; 2011 Mar; 101(3):282-96. PubMed ID: 21329999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating Flexible Modeling of Continuous Covariates in Inverse-Weighted Estimators.
    Kyle RP; Moodie EEM; Klein MB; Abrahamowicz M
    Am J Epidemiol; 2019 Jun; 188(6):1181-1191. PubMed ID: 30649165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug dosage individualization based on a random-effects linear model.
    Diaz FJ; Cogollo MR; Spina E; Santoro V; Rendon DM; de Leon J
    J Biopharm Stat; 2012; 22(3):463-84. PubMed ID: 22416835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of data transformations on concentration-response modeling.
    Weimer M; Jiang X; Ponta O; Stanzel S; Freyberger A; Kopp-Schneider A
    Toxicol Lett; 2012 Sep; 213(2):292-8. PubMed ID: 22828011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose/exposure-response modeling in dose titration trials: Overcoming the titration paradox.
    Kristensen NR; Agersø H
    CPT Pharmacometrics Syst Pharmacol; 2022 Dec; 11(12):1592-1603. PubMed ID: 36125910
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stability criteria for the outcomes of statistical tests to assess drug effectiveness with a single study.
    De Martini D
    Pharm Stat; 2012; 11(4):273-9. PubMed ID: 22422716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A powerful test for Balaam's design.
    Mori J; Kano Y
    Pharm Stat; 2015; 14(6):464-70. PubMed ID: 26214841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fitting E(max) models to clinical trial dose-response data.
    Kirby S; Brain P; Jones B
    Pharm Stat; 2011; 10(2):143-9. PubMed ID: 22432133
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Professor Endrenyi's Legacy: An Evaluation of the Regulatory Requirement "Fixed Effects, Rather Than Random Effects, Should Be Used for All Terms".
    Fuglsang A
    J Pharm Pharm Sci; 2021; 24():413-420. PubMed ID: 34343469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.